Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Edwards Lifesciences (EW)

Tipranks - Tipranks - Fri Apr 24, 8:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Regeneron (REGN) and Edwards Lifesciences (EW) with bullish sentiments.

Claim 30% Off TipRanks

Gilead Sciences (GILD)

Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences today. The company’s shares closed last Wednesday at $132.90.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.8% and a 47.2% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $159.47, which is a 19.3% upside from current levels. In a report issued on April 8, Needham also maintained a Buy rating on the stock with a $170.00 price target.

See today’s best-performing stocks on TipRanks >>

Regeneron (REGN)

In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Regeneron, with a price target of $900.00. The company’s shares closed last Wednesday at $746.58.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 9.0% and a 52.1% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Taysha Gene Therapies. ;'>

Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $877.32, representing a 16.7% upside. In a report issued on April 8, Bernstein also maintained a Buy rating on the stock with a $921.00 price target.

Edwards Lifesciences (EW)

In a report released today, Matthew Taylor from Jefferies reiterated a Buy rating on Edwards Lifesciences, with a price target of $102.00. The company’s shares closed last Wednesday at $81.53.

According to TipRanks.com, Taylor is a 4-star analyst with an average return of 6.7% and a 53.6% success rate. Taylor covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Baxter International, and Abbott Laboratories. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $96.47 average price target, a 20.4% upside from current levels. In a report issued on April 13, RBC Capital also maintained a Buy rating on the stock with a $100.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).